.jpg "Mediwound (NASDAQ: MDWD)")
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Mediwound (MDWD), with a price target of $15. The company’s shares closed yesterday at $4.89.
Olson noted:
“MDWD announced that the pivotal Ph3 DETECT study of NexoBrid for eschar removal of severe thermal burns met the primary endpoint of complete eschar removal (Exhibit 1). NexoBrid delivered an impressive 93.3% incidence of complete eschar removal on the primary endpoint which compares favorably to 4.0% for vehicle. Primary and secondary efficacy endpoints including incidence of surgical eschar removal, time to complete eschar removal and blood loss all reached a high level of statistical significance (p<0.0001), as did the safety endpoint of time to complete wound closure (p=0.0003). We consider these results a major de-risking event leading us to increase probability of success for Nexobrid in the US to 95% (from 80% prior), driving our new $15 PT (from $14 prior). Maintain Outperform, details inside."
According to TipRanks.com, Olson is ranked 0 out of 5 stars with an average return of -8.2% and a 37.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Mediwound is a Moderate Buy with an average price target of $15.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.35 and a one-year low of $3.56. Currently, Mediwound has an average volume of 254.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders.
